Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
Mark W. Tenforde, Samantha M. Olson, Wesley H. Self, H. Keipp Talbot, Christopher J. Lindsell, Jay S. Steingrub, Nathan I. Shapiro, Adit A. Ginde, David J. Douin, Matthew E. Prekker, Samuel M. Brown, Ithan D. Peltan, Michelle N. Gong, Amira Mohamed, Akram Khan, Matthew C. Exline, D. Clark Files, Kevin W. Gibbs, William B. Stubblefield, Jonathan D. Casey, Todd W. Rice, Carlos G. Grijalva, David N. Hager, Arber Shehu, Nida Qadir, Steven Y. Chang, Jennifer G. Wilson, Manjusha Gaglani, Kempapura Murthy, Nicole Calhoun, Arnold S. Monto, Emily T. Martin, Anurag N. Malani, Richard K. Zimmerman, Fernanda P. Silveira, Donald B. Middleton, Yuwei Zhu, Dayna Wyatt, Meagan Stephenson, Adrienne Baughman, Kelsey N. Womack, Kimberly W. Hart, Miwako Kobayashi, Jennifer R. Verani, Manish M. Patel, IVY Network, HAIVEN Investigators, IVY Network, Omowunmi Amosu, Brent Armbruster, Valerie Aston, Marianne Bernardo, Robert Bowers, Leslie De Souza, Jennifer Friedel, Kevin Gardner, J. Le Goff, Alexandra June Gordon, Audrey Hendrickson, Madeline Hicks, Michelle Howell, Jakea Johnson, Jeffrey L. Jorgensen, Sarah Karow, Lori Kozikowski, Olivia Krol, Leigha Landreth, Mary LaRose, Brenda López, New York, Andrea Luong, Bob McClellan, Ellen Maruggi, Karen Miller, Rahul Nair, Lisa Parks, Jennifer Peers, Cynthia Pérez, Adreanne Rivera, Jonasel Roque, Andrés Santana, Tyler Scharber, Emma Silverman, Michael Tozier, Hiwet Tzehaie, Zachary Zouyed, HAIVEN Investigators, Alejandro C. Arroliga, Alicia Bagiatis, G.K. Balasubramani, Caroline Cheng, Heather Eng, Shekhar Ghamande, Judy Herrick, Eric P. Hoffman, Kailey Hughes, Lois Lamerato, Adam S. Lauring, Amanda McKillop, Tresa McNeal
Abstract
with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19-associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%-99%) for full vaccination and 64% (95% CI = 28%-82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19-associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk.